mDETECT today announced plans to introduce its tumor-naïve, methylation-based liquid biopsy technology through a new research assay developed for Thermo Fisher Scientific’s Ion Torrent™ sequencing platforms. This highly automated NGS workflow is designed to enable circulating tumor DNA (ctDNA) analysis for lung cancer research without requiring tumor tissue samples.
Discover what’s happening
Latest News
Keep up with the latest at mDETECT
16 updates
mDETECT Inc. announces the successful closing of its $3.0 million seed financing round.
Co-founder Dr. Chris Mueller and his research team at Queen’s University have received funding from Ovarian Cancer Canada to further develop and validate our novel mDETECT-ov liquid biopsy. Designed to identify distinct DNA methylation patterns in the bloodstream, this test aims to detect ovarian cancer earlier and more accurately than traditional methods.
mDETECT has been chosen as one of Ontario’s high-potential health-tech startups supported by Ontario Genomics and FedDev Ontario’s BioCreate initiative.
Our Chief Scientific Officer, Keira Frosst won the $25,000 first place prize at AccelerateOTT with Invest Ottawa. Congrats Keira!
Our Co-founder, Dr. Wiginton won the $15,000 USD first place prize at the LG Innnofest Meeting in San Francisco
mDETECT will pitch with other seed-stage companies at OBIO
Dr. Wiginton wins first place at the Lab2Market Deep Tech Expo.
Exciting times for mDETECT and team! Check out our latest press release on our CIHR grant funding and the initiation of the multi-centre breast cancer clinical trial
In this episode, we interview one of the co-founders of mDetect Inc. - Dr. Irsa Wiginton. Dr. Wiginton holds a PhD in Biochemistry and Cell Biology from Queen's University. mDetect is commercializing a novel 'liquid biopsy' technology to support the treatment of cancer.
Dr. Mueller speaks about the mDETECT technology and its impact on cancer patients
Both our founders have been successful in several pitch competitions! Check out some of their stories below.
June 16, 2021: Queen’s researcher Christopher Mueller has developed a breast cancer detection test that provides real time response to chemotherapy and early detection of relapse.
The morning show on CKWS
Contact us
Get in TouchPartner With Us
We are actively collaborating with clinical networks, diagnostic partners, and industry leaders to bring accessible precision monitoring to market.